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Combination therapy with cisplatin and nifedipine induces apoptosis in
cisplatin-sensitive and cisplatin-resistant human glioblastoma cells
S Kondo', D Yin 1, T Moimura', H Kubol, S Nakatsu2 and J Takeuchi'
'Department ofNeurosurgery, National Utano Hospital, Kyoto 616; and 2Department ofNeurosurgery, Faculty ofMedicine,
Kyoto University, Kyoto 606, Japan.
S_mnary We attempted to determine whether calcium channel blockers (CCBs) enhance the anti-tumour
activity of cis-diamminedichloroplatinum (cisplatin) against both cisplatin-sensitive human glioblastoma U87-
MG cells and cisplatin-resistant U87-MG-CR cells, the latter of which we developed for resistance to cisplatin.
Nifedipine, a dihydropyridine class CCB, significantly enhanced the anti-tumour effect of cisplatin on these
two cell types in vitro and in vivo. Our findings also indicated that, in the absence of normal extracellular Ca2',
nifedipine was capable of enhancing the cytotoxicity of cisplatin. In addition, this anti-tumour activity was
partially inhibited by actinomycin D and cycloheximide, suggesting that it is possibly dependent upon new
RNA and protein synthesis. Interestingly. ultrastructural analysis, DNA fragmentation assay and cell cycle
analysis demonstrated that synergism between cisplatin and nifedipine results in apoptosis (programmed cell
death) at a relatively low concentration of cisplatin, which when tested alone did not induce apoptosis.
Furthermore, we demonstrated that nuclei from these cells lack a Ca-+-dependent endonuclease that degrades
chromatin in the linker region between nucleosomes. In conclusion, our studies suggest that the non-cytotoxic
agent nifedipine is able to synergistically enhance the anti-tumour effects of cisplatin on U87-MG and
U87-MG-CR cells lacking a Ca2'-dependent endonuclease and subsequently to induce apoptosis via interac-
tion of nifedipine with an as yet uncharactenrsed functional site other than a calcium channel on target cells.
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Malignant gliomas are among the most difficult human
tumours to treat successfully. Despite recent attempts to
improve chemotherapeutic approaches to their treatment,
success in the treatment of these tumours remains limited.
cis-diamminedichloroplatinum (cisplatin) is one of the more
effective and more commonly used drugs in the treatment of
malignant gliomas (Sexauer et al., 1985; Bertolone et al.,
1989). However, the effectiveness of cisplatin against recur-
rent tumours is substantially lower than against primary
tumours (Randolph et al., 1978; Amer et al., 1979), probably
because of the presence of a population of resistant cells
(Bakka et al., 1981). Recently, Gately and Howell (1993)
have reviewed several biochemical alterations that have been
reported to be capable of producing cisplatin resistance: (1)
decreased cellular accumulation of cisplatin; (2) overexpres-
sion of cell-surface glycoprotein analogous to P-glycoprotein
and inversely related to the accumulation of cisplatin; (3)
increased levels of glutathione (GSH) or of glutathione-S-
transferase activity; (4) increased levels of intracellular metal-
lothioneins (MTs); and (5) enhanced DNA repair (Kelly and
Rozencweig, 1989; Andrews and Howell, 1990; Kawai et al.,
1990; Perez et al., 1990; Timmer-Bosscha et al., 1992). How-
ever, the mechanism of resistance to the cytotoxic effect of
cisplatin is not yet clear.
Many investigators have already reported that calcium
channel blockers (CCBs) are able to enhance the cytotoxic
effect of anti-cancer agents in treatment of drug-resistant
tumours (Tsuruo et al., 1982; 1983; Tsuruo, 1983; Helson,
1984; Kessel and Wilberding, 1985). Recently, Ikeda et al.
(1987) have reported that verapamil enhances the anti-
tumour effect of cisplatin on human neuroblastoma cells.
Onoda et al. (1986, 1988, 1989) have also reported that
nifedipine enhances the cytotoxic anti-tumour effects of cis-
platin on cisplatin-sensitive and cisplatin-resistant murine
melanoma cells and their pulmonary metastases. We have
therefore attempted to determine whether CCBs enhance the
cytotoxicity of cisplatin for cisplatin-sensitive and cisplatin-
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resistant human glioblastoma cells in vitro and in vivo. Fur-
thermore, in studying the mechanism responsible for the
synergism between cisplatin and CCB, we have attempted to
determine whether, in the absence of normal extracellular
Ca'+, CCBs are capable of enhancing the cytotoxicity of
cisplatin.
Recent studies have demonstrated that cisplatin induces
apoptosis (programmed cell death) in Chinese hamster ovary
cell lines (Barry et al., 1990: Eastman. 1990) and in a human
pre-B-cell leukaemia line 697 (Miyashita and Reed, 1993).
We therefore attempted to determine, using ultrastructural
analysis, DNA fragmentation assay and cell cycle analysis,
whether the combination chemotherapy with cisplatin and
CCB induces apoptosis in glioblastoma cells. We also
attempted to determine whether cell death induced by this
synergism is due to the activation of endogenous Ca' 2-
dependent endonuclease.
Materias and methods
Tumour cells
U87-MG glioblastoma cell lines were obtained from Riken
Cell Bank (Wako, Japan). The cisplatin-resistant U87-MG
(U87-MG-CR) cells were developed by a modification of the
protocol of Schmid et al. (1980). First, U87-MG tumour was
transplanted subcutaneously into Balb c (nu/nu) female
athymic nude mice on day 1. Sequential treatment of sub-
cutaneous tumours with two courses of intraperitoneal cis-
platin (2 mg kg-1) on days 14 and 21 was then undertaken.
On day 28, tumours were excised and adapted for growth in
culture as previously described by Onoda et al. (1986). The
resulting cultures were treated with incrementally increasing
(0.3-1.2;m) exposures to cisplatin. Typically, exponentially
growing cells were treated for 1 day with cisplatin; this was
followed by removal of cisplatin, and then readdition at the
next highest dose. The cells which survived the in vitro cis-
platin treatment were retransplanted into nude mice sub-
cutaneously. Mice bearing the resulting tumours were also
treated with the same two courses of cisplatin. On day 28,
tumours were excised and used to form cultures in vitro as
described above. Cells were then also treated with incremen-tally increasing (1.2-2.1 #IM) exposures to cilatin. The sur-
viving cisplatin-resistant cells were designated U87-MG-CR
cells. U87-MG-CR cells were routinely exposed (in vitro) to a
2.1 DIM dose of cisplatin to mantain the cisplatin-resistant
character of the lines. Tumour cells were cultured in DMEM
(Nissui, Tokyo, Japan) supplemented with 10% heat-
incivated FCS (Gibco, Grand Island, NY, USA), 4mM
glutamine, 50 U ml- penicillin and 34 DM streptomycin.
Tumour cells were harvested by overlaying the monolayer
with a solution of 0.05% trypsin and 0.53 mM EDTA
(Gibco).
Cisplatin and CCBs
Cisplatin was supplied by Nippon Kayaku (Tokyo, Japan).
The CCBs used were as follows: nifedipine, nimodipine and
nisoldipine supplied by Bayer Yakuhin (Osaka, Japan); nicar-
dipine supplied by Yamanouchi Pharmaceuticals (Tokyo);
benidipine supplied by Kyowa Hakko Kogyo (Tokyo); nil-
vadipine supplied by Fujisawa Pharmaceuticals (Osaka); dil-
tiazem supplied by Tanabe (Osaka); and verapamil suWlied
by Eisai (Tokyo).
In vitro anti-tunour studies
The inhibition of tumour cell viability by either isplatin
alone or combination with cisplatin and CCB was evaluated
by determining the number of viable cells, expressed as the
number of trypan blue-excluding cells counted in a
haemocytometer. Tumour cells were seeded at 101 cells per
well (1.0 ml) in 24-well plates (Corning, NY, USA) and
incubated overnight at 3rC. In order to determine the pro-
tocol of combination therapy with CCBs and cisplatin to be
used in this study, cells were treated with CCBs (30 DIM)
either 20 min before, simultaneous with or 20 min after asp
latin treatment. Results indicated that pretreatment of cells
wtih CCBs 20 min prior to isplatin treatment was associated
with the maximum anti-tumour effect (data not shown). Each
day an aliquot was examined microscopically.
In vivo anti-tumour studies
Balb/c nude mice received subcutaneous injections of 5 x 106
exponentially growing U87-MG or U87-MG-CR cells in the
right flank on day 1. The tumour was permitted to establish
on day 14, and CCB alone (10 mgkg'), cisplatin alone
(5mg kg-1) or a combination of CCB and cisplatin was
administered intraperitoneally on days 14, 16, 20, 23 and 27.
For combination therapy with CCB and cisplatin, CCB was
administered 20 min before the injection ofcisplatin. Control
mice each received an intraperitoneal injection of sterile
phosphate-buffered saline (PBS). The growth of tumour was
monitored with the use of calipers at 2- or 3-day intervals.
Tumour volume (v) was caklulated as (L x W")/2, where
L = length (mm) and W = width (mm). All control groups
contained four mice, as did each of the treatment groups.
Effect ofcisplatin and CCB in Ca2+-free medin
Tumour cells cultured in Ca2+-free DMEM (Gibco) were
treated with cisplatin and nifedipine as described above.
Viability was determined at each time point by trypan blue
exclusion.
Inhibition ofRNA andprotein synthesis
To determine whether inhibition of RNA or protein synthesis
results in inhibition of the cytotoxicity induced by combina-
tion therapy with cisplatin and nifedipine, U87-MG and
U87-MG-CR cells were pretreated for 5 min with actino-
mycin D (48 DuM or 64 DM) or cylcoheximide (2.8 Jim or
3.5gM), respectively, prior to combination therapy. Higher
concentrations of actinomycin D and cycloheximid caused
cytotoxcity in tumour cells by themselves. Viability was
determined at each time point by trypan blue exclusion.
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Apoptoticfeatures oftunour cells treated with cisplatun and
nifedipine
To determine whether tumour cells treated with cisplatin and
nifedipine display a typical apoptotic morphology, treated
tumour cells were examined at the ultrastructural level as
previously described (Kondo et al., 1994a). Briefly, 2 x 10'
tumour cells were harvested, washed in PBS, pelleted,
prefixed in 2.0% glutaraldehyde for 2 h and washed in 0.1 M
phosphate buffer (pH 7.4), followed by post-fixation with
1.0% osmium tetroxide for 2 h. Samples were embedded in
Econ 812, sectioned and stained for 20 min in 2.0% aqueous
uranyl acetate and for 2 min in lead citrate. Grids were
viewed using a JEM-1200EX ekctron microscope (NEC,
Tokyo, Japan). Furthermore, DNA fragmentation assay was
performed using methods described previously (Kondo et al.,
1994b). Briefly, harvested cells (1 x 10') were centrifuged and
washed twice with cold PBS. The cell pellet was lysed in
l.Oml of a buffer consisting of 10mm Tris-HCI, 10mM
EDTA and 0.2% Triton X-100 (pH 7.5). After 10 min on ice,
the lysate was centrifuged (13 000g) for IOmin at 4C in an
Eppendorf microtube. Then, the supernatant (containing
RNA and fragmented DNA, but not intact chromatin) was
extracted first with phenol and then with phenol-chloro-
form-isoamyl alcohol (24:1). The aqueous phase was made
up to 300 mM sodium chloride and nucleic acids were
precipitated with two volumes of ethanol. The pellet was
rinsed with 70% enthanol, air dried and then dissolved in
20#lI of 10 mM Tris-HCI and 1 mM EDTA (pH 7.5). After
digesting RNA with RNAse A (44 tM, at 3TC for 30min),
the sample was electrophoresed in a 2% agarose gel with
Boyer's buffer (50 mM Tris-HCI, 20 mM sodium acetate,
2 mM EDTA and 18 mm sodium chloride, pH 8.05). DNA
was then visualised with ethidium bromide staining. In.addi-
tion, DNA fragmentation was expressed as the amoiunt of
soluble (fragmented) DNA recovered as a percentage oftotal
(fragmented and intact) DNA.
Flow cytometry
Apoptosis was quantitated by flow cytometric method des-
cribed previously (Yin et al., 1994). Approximately 2.0 x 10'
treated tumour cells were fixed with 2 ml of 70% ethanol on
ice for 15min, pelleted and stained with propidium iodide
(75DM in PBS) containing 37IM RNAse A for an additional
30min on ice, prior to analysis of DNA content by flow
cytometry. Cells were tested for cell cycle position using a
FACScan flow cytometer (Becton Dickinson, Mountain
View, CA, USA) equipped with CellFIT version 2.0 software.
The SOBR (sum ofbroadened rectangles) model provided by
this software was used to estimate the percentage of cells in
each phase of the cell cycle. This model uses a complex
repetitive calulation to produce approximations to the
actual histogram, fitting GO/G, and G2/M populations with
single Gaussian curves.
Isolation ofnuclei anddetermination ofendogenous nuclease
activity
This assay was performed using methods described pre-
viously (Rodriguez-Tarduchy et al., 1992). Briefly, 5 x 10'
tumour cells were pelleted and the nuclei were prepared by
resuspension in 10 mM Tris-HCI, 1.5 mM magnesum
chloride, pH 7.2, and incubation on ice for 60min. After
washing in 1.5 mm magnesium chloride, nuclei were resus-
pended in 10mm Tris-HCl, 200mM sucrose and 140mM
sodium chloride, pH 7.2. Endogenous nuclease activity was
determined after incubation of the suspension of nuclei for
4 h at 37C in the absence or presence of 5 mM calcium
chloride and 10mM magnesium chloride. As a control for
degradation of chromatin in oligonucleosome-length frag-
ments, micrococcal nuclease (10 Uml', Sigma, St Louis,
MO, USA) was added, and the nuclei were incubated for
10 mm in the presence of 5 mM calcium chlonde and 10mM
magnesium chloride. Following the incubation, fragmented- .MOPink - O~ cdbby Kdond a ubp
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DNA was extracted and analysed as descibed above. We
also studied the effect of calcium ionophore A 23187 (Sigma)
on the viability of tumour cells, sinc A 23187 has been
reported to stimulate increases in the concentration of
cytosolic Ca2+ which in turn can induce apoptosis of cells
with Ca2-dependent nuclease (Cohen and Duke, 1984;
McConkey et al., 1989).
Statistical analysis
The statistical signince of findings was assessed using the
paired Student's t test.
Resdts
In vitro anti-tumour effects ofcisplatin and CCBs
As shown in Figure 1, the IC,O (the concentration at which
50% inhibition of cell viability can be induced when treated
for 72 h as compared with controls) of asplatin for U87-MG
and U87-MG-CR cells was 20pM and 100IM rvely.
We therefore suggest U87-MG-CR cells are more istant to
cisplatin than U87-MG cells. Then, U87-MG and U87-MG-
CR cells were treated wtih cisplatin alone (15 of 3011M) or a
combination of cisplatin and CCB (30,M) respectively. As
shown in Figure 2a and b, the combination of cisplatin and
nifedipine inhibited the cell viability of both U87-MG and
U87-MG-CR cells signiicantly more than did cisplatin alone
in a time-dependent manner (P<0.005 and P<0.01 respec-
tively). Diltiazem, though less effective than nifedipine, also
enhanced the anti-tumour effect of isplatin more than did
cisplatin alone (P<0.05, each comparison). CCBs alone had
no signifiant effect on the cell viability ofeither U87-MG or
U87-MG-CR cells (data not shown).
In vivo anti-tumour effects ofcisplatin and CCBs
Following the finding of significant anti-tumour effects for
cisplatin in combination with either nifedipine or diltiazem in
vitro, we studied anti-tumour activity in vivo with the trans-
planted U87-MG and U87-MG-CR cells. As shown in
Figure 3a, cisplatin alone had by day 35 reduced the tumour
volume of U87-MG cells significntly when compared with
the control group (P<0.1). Furthermore, by day 35 com-
bination therapy with isplatin and nifedipine had resulted in
a significantly greater reduction in U87-MG tumour volume
than had either control treatment or treatment with cisplatin
alone (P<0.005 and P<0.01 respectively). This combina-
tion therapy did not induce regression of the tumour, but did
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suppress tumour growth until day 35. The combination of
cisplatin and diltiazem had no effect on tumour volume.
Neither nifedipine alone nor diltiazem alone also had any
effect on tumour volume (data not shown). Cisplatin alone
also had no effect on U87-MG-CR tumour volume (Figure
3b). In contrast, the combination of cisplatin and nifedipine
reduced tumour volume signiiantly more than did control
treatment (P<0.05). Similarly, nifedipine alone, diltiazem
alone and the combination of cisplatin and diltiazem each
had no effect on tumour volume.
Role ofextracelluiar Ca" in the effect ofsynergism
To determine whether nifedipine synergstialy enhances the
anti-tumour activity of cisplatin aginst U87-MG and U87-
MG-CR cells owing to its effect on either a calcium channel
or some other functional site, tumour cells cultured in Ca2+-
free DMEM were assayed for cell viability. As shown in
Figure 4, in the absence of normal extracellular Ca2+,
nifedipine was also capable of enhancing the cytotoxicity of
cisplatin against U87-MG and U87-MG-CR cells when com-
pared with treatment with cisplatin alone (P<0.005 and
P<0.01 respectively).
Inhibition ofcytotoxicity by actinomycin D andcyclohexinide
As shown in Figure 5, actinomycin D and cycloheximide
appeared to provide partial protection from combination
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Fugwe 1 The cytotoxic effect ofcisplatin (0.03-150 a) for 72 h
on U87-MG (0) or U87-MG-CR cels (A). Tumour cells were
seeded at a density of 101 ceilsml'- and incubated at 3rC.
Viabity was determined by trypan bhle excuion. Values repr-
sent the means ± s.d of results of three experiments
Fugwe 2 The effect of the calium channel blockers nifedipine
(A), ( ), nilvadi
(-), nisolkpine (x), diltiazn (+) and verapamil (*), at a
concentation of 30 1M, each in combination with cisplatin (15 or
30pa), on U87-MG (a) and U87-MG-CR cel (b). (0) tes
the treatment with cisplatin alone. Tumour cells wier seeded at a
denity of 0I cells ml-' and incubated at 3TC. Viability was
determined by typan blue exdusion Vahles reprsent the
means ± sd. of results of three experiments
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Fugue 3 The effect of 10mg kg-' of the calcium channel
bockers nifedine (-) and diltialn (V), each in combination
with 5 mg kg-' c tin, on transanted U87-MG (a) and U87-
MG-CR cells (b). (A) and (0) indicate treatment without or
with csplatin alone respectively. Treatments are indicated by the
arrows. Mean tumour volumes ± sd. are shown for each group
of four Balb/c nude mice.
therapy with isplatin and nifedipine administered to both
U87-MG and U87-MG-CR cells. These findings suggest that
there was a possible requirement for RNA and protein syn-
thesis in the induction of cell death by combination therapy.
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Fge 4 The effect of extracellular Ca2+ on the synergism pres-
ent between cisplatin (15 or 30 1M) and 30 aM nifedipine, as
determined by trypan blue exclusion assay. Tumour cels were
seeded at a density of IO0 cells ml- ' and incubated at 3rC.
Values represent the means ± s.d. of results of three experimets.
In the absence of normal extracDular Ca2+, nifedipine (0) was
capable of enhancing the cytotoxicity of cisplatin ainst both
U87-MG (a) and U87-MG-CR cells (b) more than did cisplatin
alone (0) (P<0.005 and P<0.01 respectively).
Apoptoticfeatures oftumour cells treated with cisplatin and
nfepine
About 80% of U87-MG cells lost viability (Figure 1) and
frequently disnayed typical apoptotic morphology which
condensed chromatin 72 h after combination treatment
(Figure 6). In contrast, U87-MG ceLs treated with cisplatin
alone for 72 h showed almost normal viability (data not
shown). U87-MG-CR cells showed as similar results as did
U87-MG cells (data not shown). DNA fragmentation was
assesed in U87-MG and U87-MG-CR cells after treatment
for 72 h with cisplatin alone, nifedipine alone or a combina-
tion of cisplatin and nifedipine. As shown in Figure 7a and
b, no characteristic pattern of DNA fragmentation was
observed in tumour cells treated with either cisplatin alone or
nifedipine alone. In contrast, combination therapy with cis-
platin and nifedipine ckarly induced DNA fragmentation
corresponding to the nucleosome ladders characteristic of
apoptosis (Wylie et al., 1980). In addition, DNA fragmenta-
tion was observed for treatment with cisplatin alone, but
only at higher concentrations (data not shown). In addition,
the degree of DNA fragmentation by the combination in-
creased in a ime-dependent manner (Figure 7c). U87-MG
and U87-MG-CR cells treated with cisplatin and nifedipine
for 72 h showed about 75% or 65% DNA fragmentation
respectively. In contrast, U87-MG and U87-MG-CR cells
treated with cisplatin alone for 72 h showed only about 22%
or 15% DNA fragmentation respectively. Furthermore, we
examined the changes in the intensity of fluorescence of
DNA using flow cytometry. As shown in Figure 8, treatment
of U87-MG cells with ispatin alone resulted in a decrease in
the percentage of cells in GJ/G1 phase and an increase in the
percentage of cells in S and G2/M phases, compared with the
corresponding percentage for the control. On the other hand,
treatment of U87-MG cells with cisplatin and nifedipine
resulted in a decrease in the percentage of cells in G2/M
phase compared with treatment with cisplatin alone, and
moreover the accumulation of a discrete subpopulation of
signals under the GO/GI cell cycle region (AO peak).
Nuclei ofneither U87-MG nor U87-MG-CR cells contain a
Ca2 -dependent endonuclease
Since apoptosis is generally characterised by cell shrinkage,
accompanied by DNA fragmentation, owing to the activation
of Ca2+-dependent endonuclease (Duke et al., 1983), nuclei
from tumour cells were prepared and assayed for the
presence of Ca2-dependent endonuclease. Figure 9 shows
that, in nuclei prepared from tumour ceLls, the addition of
calcium did not induce cleavage of DNA into oligonucleo-
some-length fragments under our assay conditions. A positive
control experiment with murine splenocytes prepared as
previously described (Rodriguez-Tarduchy et al., 1992) dem-
onstrated that the activity of Ca2-dependent endonuclkase
was detectable in vitro in nuclei prepared from these cells. In
addition, calcium ionophore A 23187 (0.01-10gm) was
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Fugwe 5 Inhibition of cytotoxicity by actinmycin D and cyc-
obeximide, as determined using trypan blue excduion assay.
Tumour ceDls wer seded at a density of 10' celmls ' and
incubated at 37C. Vales represent the means ± s.d. ofresults of
three acperiments. Actinomyc D (48 or 64p; A) or cydohex-
imide (2.8 or 3.5pi 0) provided partial protection from the
synergim betwen cisplatin (15 or 30pi) and 30pm nifedipine
(@) in effect on U87-MG (a) and U87-MG-CR cells (b) respec-
tivdy.
incapable ofdecreasing the viability oftumour cells (data not
shown). These findings demonstrate that U87-MG and U87-
MG-CR cells each lack Ca2+-dpndent endonUceaSe.
Dis_r=S
In this study, we demonstrate that nifedipine enhances the
cytotoxicity of cisplatin in vitro and in vivo against both
cisplatin-sensitive U87-MG and isplatin-resistant U87-MG-
CR cells. Onoda et al. (1989) previously reported that
nifedipine enhances the effect of cisplatin in vitro and in vivo
on both cisplatin-sensitive and isplatin-resistant murne
melanoma cells and their spontaneous pulmonary metastases;
their findings thus support our own. On the other hand,
Ikeda et al. (1987) reported that verapamil enhances the
anti-tumour effects of cisplatin on human neuroblastoma
cells in vivo. However, our results reveal no significant syner-
gism between verapamil and cisplatin. Nifedipine may
therefore interact with a specific cellular target site.
We detected no significant synerm between cisplatin and
any of the dihydropyridine class CCBs except nifedipine.
Nicardipine and nimodipine, in particular, were ineffective
even though their kinetics for binding to the dihydropyrdine
receptor component of the calcium channel would appear to
favour their effectveness over that of nifedipme (Epstein et
al., 1982; Janis and Triggle, 1983). Onoda et al. (1989) have
Fugwe 6 Ultrastructural appearance of U87-MG cells treated
with spatin (15pM) and nifedipine (30pI) for 72h (x 7200).
Arrow indicates condensed chromatin.
also suggested that the synergism between cisplatin and
nifedipine may be the result of nifedipine's ability to alter
intracellular levels of calcium via a mechanism independent
of the voltage-sensitive calcium channel. For example, CCBs
are known to inhibit Ca24 influx into platelets, even though
platelets lack the voltage-sensitive calcium channel (Motulsky
et al., 1983; Onoda et al., 1984). Therefore, to determine
whether nifedipine synergistically enhances the cytotoxicity of
cisplatin against U87-MG and U87-MG-CR cells owing to
its effect on Ca2" influx or to an effect at some other func-
tional site, tumour cells cultured in Ca24-free DMEM were
assayed for cell viability. Our findings indicate that, in the
absence of normal extracellular Ca2", nifedipine was also
capable ofenhancing the cytotoxicity ofcisplatin for tumour
cells. This synergism may be activated by nifedipine's effect
on a functional site other than the calcium channel. How-
ever, there still remains a possibility that nifedipine may be
affecting Ca2" signalling from internal stores ofCa2" released
from the endoplsmic reticulum.
Recently, cisplatin has been shown to induce apoptosis in
Chinese hamster ovary cell lines (Barry et al., 1990; Eastman,
1990) and in a human leukaemia cell line (Miyashita and
Reed, 1993). Interestingly, in this study ultrastructural
analysis, DNA fragmentation assay and cell cycle analysis
have demonstrated clearly that synergism between cisplatin
and nifedipine results in apoptosis at a relatively low concen-
tration of cisplatin which when tested alone does not induce
apoptosis. Ormerod et al. (1994) suggest that, at relatively
lower doses of isplatin, tumour cells become blocked in
G2/M phase, and that there is a major deision point at this
stage of the cell cycle. The cells treated with cisplatin either
eventually divide or die after stay in G2/M (Sorenson et al.,
1990). Evans and Dive (1993) also suggest that initiation of
cisplatin-induced apoptosis needs to be coupled to a cell
cycle-mediated event. Our results show that the combination
with cisplatin and nifedipine induced a reduction in G2/M
phase cells when compared with cisplatin alone, and
accumulated AO peak. This peak has been shown to indicate
the presence ofapoptotic cells (Telford et al., 1991; Walker et
al., 1991; del Bino et al., 1992; Ormerod et al., 1994). Our
findings suggest two possibilities: that tumour cells blocked in
G2/M phase continue to cycle in the presence of nifedipine
and die at a later stage in the cell cycle or, alternatively, that
tumour cell death occurs directly out of GO/GI phase. In
addition, our results showing that actinomycin D and cyclo-
heximide prevented the cytotoxic effect of the combination
on tumour cells are identical to the findings of previous
reports (Sorenson et al., 1990). These agents prevented the
induction of apoptosis by cisplatin alone, at higher concen-
tration than tested (data not shown), so we suggest that these
affected not only cisplatin-induced death per se but also the
synergistic effect of nifedipine. However, the effect of cyc-
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loheximide in particular on the modulation of apoptosis is
clearly complex, and in some cell types cycloheximide induces
apoptosis (Collins et al., 1991). Evans and Dive (1993) sug-
gest that cyclohexiimide may prevent the synthesis of 'suicide'
proteins which are critical for the engagement of apoptosis
following drug-induced damage or it may prevent the syn-
thesis of inhibitors of what might be an intrinsic 'default'
programme.
In general, apoptosis is characterised by cell shrinkage
accompanied by DNA fragmentation owing to the activation
of an uncharacterised Ca2+/Mg2+ endonuclease which cleaves
the cell's DNA into nucleosome-sized units (Duke et al.,
1983; Cohen et al., 1984; Wylie, 1987). However, our
findings suggest that U87-MG and U87-MG-CR cells lack
Ca2'-dependent endonuclease, although we cannot rule out
the possibility that this assay is limited in its sensitivity and,
moreover, such an endonuclease is present in these cells but
is destroyed during the preparation of nuclei. An incon-
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Fge 7 Induction of DNA fragmentation by cisplatin alone.
nifedipine alone or a combination of cisplatin and nifedipine.
Fragmented DNA was isolated after 3 days and electrophoresed
in a 2.0% agarose gel as described in the Materials and methods
section. a, U87-MG cells were treated with cisplatin alone (lane 2,
7.5 pM; lane 4, 15 !LM) or with a combination of cisplatin and
30 FM nifedipine (lane 3 or lane 5). Alternatively, they were
treated with nifedipine alone (lane 6). b, U87-MG-CR cells were
treated with cisplatin alone (lane 2, 15 Lm; lane 4, 30 FM) or with
a combination of cisplatin and 30 FM nifedipine (lane 3 or lane
5). Alternatively, they were treated with nifedipine alone (lane 6).
Molecular weight standards of multiples of 123 bp DNA Ladder
(Gibco BRL. Tokyo) are shown in lane 1. c, The kinetics of
DNA fragmentation in U87-MG and U87-MG-CR cells induced
by cisplatin alone [15p.#m (0) or 30 lM (A)] or the combination
with cisplatin and 30 1M nifedipine [(0) or (A) respectively].
Values represent the means ± s.d. of results from three
experiments.
'a
C.) co
U)
4--
C
0
U
S
G2/M
FL2-R
Fgwe 8 Flow cytometric analysis of U87-MG cells treated
without (control, a) or with cisplatin alone (15 ELm, b) or with the
combination of cisplatin and 30 iM nifedipine (c) for 72 h.
Tumour cells were subsequently fixed and stained with propidium
iodide prior to DNA histogram analysis. In each case cell number
(ordinate) was plotted against relative fluorescence (abscissa). The
percentage of ceUls in each phase of the cell cycle at AO (a
subpopulation of signals under the GO/GI cell cycle region):
GO/GI: S: GJM; a, 0: 77: 14: 9; b, 4: 33: 39: 24; c, 18: 47: 27: 8.
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Figure 9 In vitro analysis of endonuclease activity. Nuclei from
U87-MG (lanes 2-4) or U87-MG-CR cells (lanes 5-7) obtained
as described in the Materials and methods section were incubated
for 4 h at 3TC in the absence (lane 2 or lane 5) or in the presence
(lane 3 or lane 6) of 5 mm calcium chloride and 10mm
magnesium chloride. As a control for the degradation of
chromatin into oligonucleosome-length fragments. micrococcal
nuclease (10 U mn-') (lane 4 or lane 7) was added, and the nuclei
were incubated for 10 min in the presence of 5 mmi calcium
chloride and 10 mm magnesium chloride. Following the incuba-
tion, fragmented DNA was extracted and electrophoresed in a
2.0% agarose gel. Lane 8 is a positive control with murine
splenocytes. Molecular weight stanidards of multiples of 123 bp
DNA ladder are shown in lane 1.
sistency emerges from comparison of our findings for human
glioblastoma cells with those of other groups studying lym-
phocytes or thymocytes. Indeed, T-lymphoid lineage cells
(McConky et at., 1989) and many other mammalian cell
types (Jones et at., 1989; Arends et at., 1990) contain Ca2+_
dependent endonuclease. In contrast, Rodriguez-Tarduchy et
at. (1990, 1992) have recently reported that calcium
ionophores inhibit apoptosis in the interleukin 3 (IL-3)-
dependent bone marrow-derived cell line BAF3. by maintain-
ing the cells in a viable non-cycling state. They also suggest
that whether apoptosis is induced or inhibited by calcium
ionophore depends on whether a calcium-dependent nuclease
is present in target cells. Their findings may possibly support
our own. In addition, the role of the endonuclease per se.
which cleaves to 180 bp fragments, has been called into
question recently. It appears that this type of fragmentation
is a late and even dispensable event in the apoptotic process,
and that it can be inhibited without preventing the mor-
phological changes in the nucleus (Oberhammer et al., 1993).
The combination with cisplatin and nifedipine may affect the
late process of apoptosis. On the other hand, Johnson and
Byerly (1991, 1993) have recently demonstrated that all the
Ca' channels can be blocked by the increase in intracellular
Ca>+ in neuronal cells. Therefore, the role of calcium as a
signal for apoptosis remains controversial.
In conclusion, we hypothesise that nifedipine synergis-
tically enhances the anti-tumour effect of cisplatin on both
cisplatin-sensitive and cisplatin-resistant human glioblastoma
cells and induces apoptosis in these tumour cells, via interac-
tion of nifedipine with an as yet uncharacterised functional
site other than a calcium channel on target cells. Until
recently, in clinical investigations various chemosensitisers.
including verapamil, were used as a modulation of resistance
(Ozolos et al., 1987). The main problem with this chemosen-
sitisation is the inability to attain plasma levels in patient,
corresponding with in vitro effective concentrations. because
of the observed cardiovascular toxicity (Ozolos et al., 1987).
However, our study described here suggests that, if an
uncharacterised functional site with which nifedipine interacts
is clarified, the novel chemosensitiser without major toxicities
may be applicable in the treatment of primary and recurrent
malignant gliomas because it has no use of calcium
antagonistic activity. In addition, further studies are neces-
sary to determine the mechanism of resistance in U87-MG-
CR cells and, moreover, whether nifedipine alters the
accumulation of cisplatin, the levels of GSH, the levels of
MTs and DNA repair in tumour cells.
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